The only way I'd expect raw datasets to be published online immediately in a useful, curated manner by a research group is if that was stipulated in their resea

The only way I'd expect raw datasets to be published online immediately in a useful, curated manner by a research group is if that was stipulated in their research grant, period, i.e. that's what the goal of the project was, at least in part. Now this is not entirely uncommon in many research areas; you can get all the current weather and climate datasets with little difficulty as these are shared globally (as is necessary for effective short-term weather forecasting). Anyone publishing DNA/RNA/protein work generally uploads those sequences to GenBank, and that gets updated every two months, so is pretty current relative to the published literature: https://www.ncbi.nlm.nih.gov/genbank/ https://www.ncbi.nlm.nih.gov/genbank/ However this article seems to focus on "Biomed" and that whole world is where pharmaceutical/corporate influence in academics is off the charts. I'd guess well over half of the researchers (if not over 90%) have some dream of getting their work patented, setting up a biomed startup, and having Pfizer or J&J swoop in and buy them out (they then get a percentage and become wealthy), and their university patent office is likely pushing for that as well (they get another percentage). No way are those people going to share their data, which might very well be slanted or cooked in ways that will make their little entrepreneurial effort more attractive to a big buyer. It's way more like pitching to a VC than doing actual rigorous scientific research in the tradition of open sharing of results and ideas - at least not until the patent is granted. Then you're into whether or not the clinical trial data will be released to the public, and corporations don't like to do that either (as someone might find that their claimed success story is riddled with statistical errors, etc.). Business and science have orthogonal goals, and mixing the two is almost always a recipe for the rise of fraudulent con artists pushing bogus BS in the name of turning a quick profit.